Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Blood

• Publication date

  2007-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2006-12-062422PMID 17392506PMCID PMC1896112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis1

  2006cited by this paper
• Restoring function in exhausted CD8 T cells during chronic viral infection

  2006cited by this paper
• In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses

  2005cited by this paper
• The B7 family revisited.

  2005cited by this paper
• Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes.

  2005cited by this paper
• Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4

  2005cited by this paper
• Peripheral tolerance of CD8 T lymphocytes.

  2005cited by this paper
• Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.

  2005cited by this paper
• Concomitant Helper Response Rescues Otherwise Low Avidity CD8+ Memory CTLs to Become Efficient Effectors In Vivo1

  2004cited by this paper
• Transient gain of effector function by CD8+ T cells undergoing peripheral tolerance to high‐dose self‐antigen

  2004cited by this paper
• Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.

  2004cited by this paper
• Persistent Toll-like receptor signals are required for reversal of regulatory T cell–mediated CD8 tolerance

  2004cited by this paper
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

  2004cited by this paper
• B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes.

  2004cited by this paper
• Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor

  2003cited by this paper
• PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver

  2003cited by this paper
• Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

  2003cited by this paper
• Deletion of Naive CD8 T Cells Requires Persistent Antigen and Is Not Programmed by an Initial Signal from the Tolerogenic APC 1

  2003cited by this paper
• Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1

  2003cited by this paper
• B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells

  2001cited by this paper
• A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis.

  2001cited by this paper
• Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

  2001cited by this paper
• PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine

  2001cited by this paper
• Cross-presentation, dendritic cells, tolerance and immunity.

  2001cited by this paper
• In Vivo CD4+ T Cell Tolerance Induction Versus Priming Is Independent of the Rate and Number of Cell Divisions1

  2000cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• Inhibition of VEGF receptors causes lung cell apoptosis and emphysema.

  2000cited by this paper
• Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

  1999cited by this paper
• CD4+ T Cell Tolerance to Parenchymal Self-Antigens Requires Presentation by Bone Marrow–derived Antigen-presenting Cells

  1998cited by this paper
• Class I–restricted Cross-Presentation of Exogenous Self-Antigens Leads to Deletion of Autoreactive CD8+ T Cells

  1997cited by this paper
• The emerging role of CTLA-4 as an immune attenuator.

  1997cited by this paper
• CD8(+) T cell-mediated spontaneous diabetes in neonatal mice.

  1996cited by this paper
• Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

  1995cited by this paper
• Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4

  1995cited by this paper

• PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy

  2025cites this paper
• Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective

  2025cites this paper
• Role of PD‐1 in Skin Cancer: Molecular Mechanism, Clinical Applications, and Resistance

  2024cites this paper
• Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta‐analysis

  2024cites this paper
• Immune microenvironment in papillary thyroid carcinoma: roles of immune cells and checkpoints in disease progression and therapeutic implications

  2024cites this paper
• The CD8+ T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defects.

  2024cites this paper
• From foes to friends: rethinking the role of lymph nodes in prostate cancer

  2024cites this paper
• Advancements in nanomedicine delivery systems: unraveling immune regulation strategies for tumor immunotherapy.

  2024cites this paper
• Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.

  2023cites this paper
• Evolving strategies and application of proteins and peptide therapeutics in cancer treatment.

  2023cites this paper
• Unraveling the Role of Epithelial Cells in the Development of Chronic Rhinosinusitis

  2023cites this paper
• A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors

  2023cites this paper
• A novel humanized PD-1/PD-L1 mouse model permits direct comparison of anti-tumor immunity generated by FDA-approved PD-1 and PD-L1 inhibitors

  2022cites this paper
• Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients

  2022cites this paper
• The role of long non-coding RNA FGD5-AS1 in cancer

  2022cites this paper
• Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy

  2022cites this paper
• Therapeutic Applications of the Cancer Immunoediting Hypothesis.

  2021cites this paper
• Tumor and Systemic Immunomodulatory Effects of MEK Inhibition

  2021cites this paper
• The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma

  2021cites this paper
• Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint

  2021cites this paper
• Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?

  2021cites this paper
• A snapshot of the PD-1/PD-L1 pathway

  2021cites this paper
• The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era.

  2021cites this paper
• Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer

  2021cites this paper
• Treatment Strategies of Gastric Cancer—Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review

  2021cites this paper
• Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy

  2021cites this paper
• Sustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma

  2021cites this paper
• Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression

  2020cites this paper
• Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy

  2020cites this paper
• Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy

  2020cites this paper
• Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression

  2020cites this paper
• PD-L1 Expression Enhancement by Tumor-Associated Macrophages Derived Osteopontin Leads to Poor Non-Small Cell Lung Caner Prognosis

  2020cites this paper
• Programmed cell death ligand‐1: A dynamic immune checkpoint in cancer therapy

  2020cites this paper
• PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer

  2020cites this paper
• Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints

  2020cites this paper
• A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies

  2020cites this paper
• The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities.

  2020cites this paper
• Neoadjuvant checkpoint blockade for cancer immunotherapy

  2020cites this paper
• Neoadjuvant Chemoimmunotherapy in Resectable IIIA/IIIB Non-small Cell Lung Cancer

  2020cites this paper
• Assessment of IFN-γ and granzyme-B production by in "sitro" technology.

  2020cites this paper
• Advances in immune neoadjuvant/adjuvant therapy‐related adverse events of non‐small cell lung cancer

  2020cites this paper
• CMAR_A_257188 6493..6509

  2020cites this paper
• Science Journals — AAAS

  2020cites this paper
• Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes

  2020cites this paper
• Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer

  2020cites this paper
• Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers

  2020cites this paper
• OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody

  2020cites this paper
• Immunotherapy in advanced gastric cancer, is it the future?

  2019cites this paper
• Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma

  2019cites this paper
• Paradox-driven adventures in the development of cancer immunology and immunotherapy

  2019cites this paper
• Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

  2019cites this paper
• 1-1-2017 PD-1 , PD-L 1 ( B 7-H 1 ) and Tumor-site Immune Modulation Therapy : the Historical Perspective

  2019cites this paper
• CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

  2019cites this paper
• Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?

  2019cites this paper
• In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1.

  2019cites this paper
• Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer

  2019cites this paper
• Immune Checkpoint Molecules and Cancer Immunotherapy

  2019cites this paper
• Co-signal Molecules in T-Cell Activation : Historical Overview and Perspective.

  2019cites this paper
• YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.

  2019cites this paper
• Inhibitors of the PD-1 Pathway in Tumor Therapy

  2018cites this paper
• Neoadjuvant PD-1 blockade in lung cancer: we're not in Kansas anymore.

  2018cites this paper
• Tipping the balance: inhibitory checkpoints in intestinal homeostasis

  2018cites this paper
• Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer

  2018cites this paper
• Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers

  2018cites this paper
• Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy

  2018cites this paper
• Immunotherapy for Prostate Cancer: An Evolving Landscape

  2018cites this paper
• Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

  2018cites this paper
• Vaccine therapy and immunotherapy for pancreatic cancer

  2018cites this paper
• Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.

  2018cites this paper
• Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity.

  2018cites this paper
• THE ROLE OF SUBPOPULATIONS OF CD8+ T LYMPHOCYTES IN THE DEVELOPMENT OF PREGNANCY

  2018cites this paper
• Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells

  2017cites this paper
• Costimulation, a surprising connection for immunotherapy

  2017cites this paper
• PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective

  2017cites this paper
• Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.

  2017cites this paper
• PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways

  2017cites this paper
• Immune checkpoint inhibitors in renal cell carcinoma

  2017cites this paper
• Tc 17 CD 8 T Cells : Functional Plasticity and Subset Diversity 1

  2017cites this paper
• PD-1 and B7-H1 Expression after Show Differential Effects Correlating with T Cells + Regulatory and Conventional CD4

  2017cites this paper
• Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy

  2017cites this paper
• PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

  2017cites this paper
• IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

  2016cites this paper
• Clinical utility of nivolumab in the treatment of advanced melanoma

  2016cites this paper
• Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy

  2016influential citation
• PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-κB.

  2016cites this paper
• Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) Regulates Dendritic Cells and Myeloid Derived Suppressor Cells Development in the Lymphoma Microenvironment

  2016cites this paper
• Subset- and Antigen-Specific Effects of Treg on CD8+ T Cell Responses in Chronic HIV Infection

  2016cites this paper
• TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.

  2016cites this paper
• Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.

  2016cites this paper
• Immune checkpoint blockade: a common denominator approach to cancer therapy.

  2015cites this paper
• Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

  2015cites this paper
• T Cell Fate in the Tumor Microenvironment

  2015cites this paper
• TGF-BETA1/SMAD3 SUPPRESS ANTI-TUMOR IMMUNITY BY ENHANCING PD-1 EXPRESSION ON ANTIGEN-SPECIFIC CD8+ T CELLS IN CANCER

  2015cites this paper
• Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?

  2015cites this paper
• Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment

  2015cites this paper
• Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy

  2015cites this paper
• Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer.

  2014cites this paper
• Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer.

  2014cites this paper
• B7-H1 signaling is integrated during CD8+ T cell priming and restrains effector differentiation

  2014cites this paper
• Highly Pathological Influenza A Virus Infection Is Associated with Augmented Expression of PD-1 by Functionally Compromised Virus-Specific CD8 (cid:2) T Cells

  2014cites this paper